Transdermal Glomerular Filtration Rate
MED201.050
This policy addresses noninvasive transdermal measurement of glomerular filtration rate using the MediBeacon Transdermal GFR (TGFR) system with relmapirazin (Lumitrace) for point-of-care GFR assessment in adults with normal or impaired kidney function. The policy is inactive and treats TGFR as experimental/unproven with limited early-stage (phase II) evidence and practical limitations — it is not covered here, is not approved/validated for patients on dialysis, anuric patients, GFR <15 or >120 ml/min/1.73 m², rapidly changing renal function, or pediatric/older-than-studied populations, and has reported issues such as sensor adhesion failures and potentially insufficient 12-hour monitoring.
"Non-invasive assessment of glomerular filtration rate (GFR) in adults with normal or impaired kidney function using the MediBeacon Transdermal GFR (TGFR) system."
Sign up to see full coverage criteria, indications, and limitations.